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1. BACKGROUND 
Silicone injection for cosmetics and surgery is still widely practiced in Indonesia. The result of 
Indonesian Association of Plastic Surgeons survey start from 2004 to 2007, found 249 cases 
of silicone complications.1 Epidemiological data in other countries was not clear because 
silicone injection had been banned. In 1990, more than 100,000 patients in United States had 
received silicone injection in their face.3 In Indonesia, there had been no research on silicone 
injection and its complications, although the cases were abundant. The use of silicone injection  
for cosmetic treatment had been banned by Federal Food, Drug & Cosmetic America (FDA) 
since 1992.3 Liquid silicone which was injected into the skin can migrate and cause 
morphological changes and uncontrolled inflammatory response. Liquid silicone in the tissue 
is persistent, so it will lead to chronic inflammation and granulomas formation, if severe, it 
could be followed by infection, necrosis, and abscess.2-4 Silicone granuloma is difficult to 
evacuate and is still able to form new granuloma after the evacuation. Immune response of 
granuloma is mediated by T cells, Th1 secreted pro inflammatory cytokines and Th2 secreted 
anti inflammatory cytokines.18  The new theory of immune tolerance played by Tregs 
(CD4+CD25+) and Indoleamine-2,3-dioxygenase enzyme might be explained obviously the 
pathogenesis of granuloma formation due to silicone injection.21-24 Until now, the pathogenesis 
of silicone granuloma has been studied, but the result are still controversial. The aimed of this 
study is to analyse the phatogenesis of silicone granuloma in respect to immune inflammatory 
response and tolerance.  
 
2. METHOD OF STUDY 
Descriptive analytic method was conducted in this study, which included: (1). Cross-sectional 
study, to compare immune response in three groups, namely the chin granuloma tissue, 
submental skin and skin tissue from healthy individuals (control), and to assess the clinical 
correlation, histopathological, and immune responses. Samples were 31 cases of silicone 
granulomas tissue and submental skin, and 37 normal skin tissue. All  tissues were examined 
histopathologically (HE staining) to see the degree of foreign body reaction (FBR) and 
immunohistochemistry to assess the expression of TNF-α, IFN-γ, IL-10, IDO, and Treg cells 
CD4+CD25+; (2). Laboratory experimental performed to assess blood cytokine levels with: (a) 
Culturing whole blood cells from granuloma patient and normal individuals, using RPMI 
medium, RPMI stimulated by PHA, and stimulated by 3% of silicone industry. (b) Examined 
cytokine levels from cell culture supernatant on day 3, included TNF-α, IFN-γ, and IL-10. All 
analyzed with Luminex and IDO with ELISA. The research was conducted in specialist clinics, 
Faculty of Mathematics and Sciences University of Indonesia, Faculty of Medicine University 
of Indonesia, Faculty of Medicine Airlangga University, and Eijkman Institute, start from 
November  2012 until September 2014. 
 
3. RESULT AND DISCUSSION 
Generally, patients with silicone injections in their chin were injected in the salon. They came 
for treatment approximately 12.5 years after injection, shape of chin changed in 4th years, the 
color of the skin changed in 5th years. Nose and chin were main area of silicone injections, 
54.8% of patients with silicone injection complications were not know that the injected 
substance was liquid silicone. Silicone was also present in normal skin with statistical mean 
44,07µg/g, while the silicone level in the submental skin (944 µg/g)  was significantly higher 
than the silicone level in the granuloma (688 µg/g).  
There was no significantly difference in the levels of TNF-α, IFN-γ, IL-10 and IDO from blood 
cultures stimulated by 3% of liquid silicone compared with negative control. Differences seen 
significantly between negative control and the positive control (PHA), (p<0.001). 
There was significantly difference in the expression of TNF-α, IFN-γ, IL-10 and IDO on 
inflammatory cells surface in normal skin compared with granuloma or submental skin of 
granuloma (p<0.001). However, there was no significantly difference between granuloma and 
submental skin of granuloma. In contrast, There was no significantly difference in Tregs 
population between granuloma and normal skin, but there was significantly difference between 
normal skin and submental skin of granuloma (p<0.001). 
Histopathological features (with HE staining) of normal skin tissue showed that giant cells and 
fibrosis area was not found. Histopathologic features of granuloma showed that granuloma 
tissue more inflammative than submental skin of granuloma tissue. 
Correlation between immune response in chin granuloma due to silicone injections, 
submental skin and blood. 
Based on a significant correlation between the expression of cytokines TNF-α, IFN-ɣ, IL-10 
and IDO on inflammatory cell surface in chin granuloma, submental skin of granuloma and 
normal skin with cytokines levels in blood, thus the minor hypothesis 1.  
Correlation between immune response in chin granuloma due to silicone injections with 
submental skin. 
Based on the correlation between the expression of cytokines TNF-α, IFN-ɣ, IL-10 and 
immune tolerance (Treg cells (CD4+CD25+), IDO in chin granuloma and  submental skin of 
granuloma, minor hypothesis point 2 was accepted. 
1. There was a significant correlation between histopathologic features of granulomas 
with submental skin of granuloma (p=0.004, r=0.507), due to silicone spreading, thus 
the foreign body reaction also occured in the submental skin of granuloma (Table 2). 
2. Anti inflammatory cytokines in submental skin of granuloma were significantly 
correlated with cytokines level in granulomas tissue. Level of IL-10 in submental skin 
of granuloma correlated significantly with IL-10 in granuloma tissue (p=0.021, 
r=0.412), IDO in submental skin of granuloma significantly correlated with almost all 
cytokines (TNF-α p=0.009, r=0.460; IFN-γ p=0.003 r=0.512; IL-10 p=0.012; r=0.445; 
IDO p=0.026 r=0.399). Population of Treg cells in submental skin of granuloma was 
significantly correlated with the expression of IDO on inflammatory cell surface in 
granuloma (p=0.034, r=0.381) (Table 3). Based on these results, the submental skin of 
granuloma occurs immune tolerance to prevent damage due to inflammation by 
silicone. 
Histopathological features of chin granulomas and submental skin of granuloma related 
with period of injection, silicone levels and the degree of clinical severity 
Based on correlation of histopathological features of chin granulomas and submental skin with 
period of injection, silicone levels and clinical severity, so the hypothesis minor 3 points 2, 
3, 4 are accepted. 
1. Clinical severity was not associated with  and silicone levels in patient with chin granuloma 
caused by silicone. The degree of clinical severity was not determined by period of silicone 
injection or silicone level, but by individual immune response. 
2. Histopathologic features with three phases of granuloma significantly associated with 
clinical severity (p=0,020ch*). When clinical features became more severe, 
histopathological features tends to be fibrosis (r=0.456, p=0,010s*, R2=0.207) (Figure 4) 
3. Histopathological features with eight stages of granuloma significantly associated with 
period of silicone injection in granuloma tissue (p = 0.020), and submental skin of 
granuloma (p=0.046) (Figure 5). Peak of inflammation was reached around 10-19 years 
after silicone injection and decreased after 19 years due to individual immune tolerance. 
4. Histopathological features with eight stages of granuloma significantly associated with 
higher levels of silicone in submental skin of granuloma (p=0.047), but not in the granuloma 
tissue. it can be seen in figure 4.10, that the inflammation increased concomitantly with 
silicone level in submental skin of granuloma and shifted toward fibrosis gradually when 
silicone started to be decreasing.20,23,27 Silicone level in submental skin of granuloma was 
more stable than in granuloma tissue. 
 
The role of pro inflammatory and anti inflammatory cytokines to the occurrence of 
immune tolerance in patients due to silicone injections into their chin, which is assessed 
in granuloma tissue, skin and blood 
Based on the correlation between Treg (CD4+CD25+) population as immune tolerance 
properties, expression of IDO on inflammatory cell surface in granuloma tissue and submental 
skin with period of silicone injection and silicon level, the minor hypothesis 4 was accepted, 
described in table 4 and 5. 
Expression of IDO on inflammatory cell surface did not correlate with period of silicone 
injection and silicone level. Population of Treg cells did not correlate with period of silicone 
injection, but Treg population in granuloma tissue correlated significantly with silicone level 
(p=0.033, r=0.383), (Table 4 and 5). Each individual have a difference immune tolerance, 
depend on antigen level. Silicone need plasma proteins on its surface to trigger immune 
responses. Phases of protein adsorption on silicone surface are dynamic process and difficult 
to be predicted.31 Patients with chin silicone injection have delayed-type hypersensitivity 
(DTH) reaction which would recruit lymphocytes. Silicone captured by lymphocytes via its 
receptor, then lymphocytes secreted both proinflammatory and antiinflammatory cytokines, 
and then, in this process, Treg played a role to mantain homeostasis, thus  the silicone level 
correlated with Treg population in granuloma tissue. 27 
Based on the correlation between the expression of IDO on inflammatory cell surfacein 
granuloma tissue, submental skin of granuloma and blood with clinical and histopathologic 
severity, then the minor hypothesis 5 was accepted and can be seen in table 6. 
Histopathologic features of granulomas were not associated with the expression of IDO on 
inflammatory cell surfacein granulomas, and whole blood culture with all stimulants, but 
histopathologic with eight phases in submental skin of granuloma was associated significantly 
with the expression of IDO on inflammatory cell surface in the submental skin of granuloma 
(p=0.038, Table 6). Expression of IDO on inflammatory cell surface in the submental skin of 
granuloma correlated with almost all cytokines in granuloma tissue. It is not surprising if IDO 
also correlated significantly with histopathological features. IDO seems to play an important 
role in the submental skin of granuloma so that IDO can be used as predictive tool for immune 
tolerance to silicone injection. 
Treg did not associate with histopathologic and clinical severity, but Treg population in 
submental skin of granuloma significantly associated with clinical severity (p=0.011, Table 7). 
Minor hypothesis 6 is accepted, so, Treg population in the submental skin of granuloma can 
be used as predictive tool for observing the immune response and clinical features. 
Based on the correlation between IDO and TNF-α and IFN-ɣ, in chin granuloma, submental 
skin of granuloma, as well as the blood level of cytokines, then the minor hypothesis at point 
seven is accepted and can be seen in Table 8. 
1. Level of pro inflammatory cytokines, TNF-α and IFN-γ, in whole blood culture is not 
associated with the expression of IDO on inflammatory cell surface in both tissues but the 
expression of proinflammatory cytokines, TNF-α and IFN-γ, in granuloma significantly 
correlated with the expression of IDO in both tissues (TNF-α, r=0.592, p<0.001; IFN-γ, 
r=0.603, p<0.001, table 8). IDO has a primary role in submental area for controlling 
inflammation from silicone-consuming macrophages with IDO secretion and helps to 
mantain immune tolerance, so tissue damage caused by inflammation could be prevented.32-
34 IDO activity can be used as predictive tool for observing immune response in granuloma. 
2. Treg population did not correlate with TNF-α and IFN-γ in granuloma tissue and submental 
skin of granuloma, also in blood plasma, as well as silicone-stimulated blood, but Treg 
population in granuloma inversely correlated with TNF-α and IFN-γ in PHA-stimulated 
blood (TNF-α, r= -0.450, p=0.011; IFN-γ, r= -0.367, p=0.042). Lymphocytes will be 
stimulated by PHA. Treg cells are subset of lymphocytes that will mantain immune 
tolerance in granuloma caused by silicone injection. Inverse correlation happen because 
Treg works as an anti inflammatory, whereas TNF-α and IFN-γ are pro inflammatory 
cytokines.17,27 
Based on the correlation between Treg population (CD4 +CD25+) and IDO with ratio TNF-
α/IL-10 and IFN-ɣ/IL-10 in whole blood culture and both tissue, then minor hypothesis at point 
eight is accepted and described on the table 9. 
1. IDO in granuloma and submental skin of granuloma did not correlate to the ratio of TNF-
α/IL-10 and IFN-γ/IL-10 in blood plasma and PHA-stimulated blood, as well as granuloma 
tissue but the IDO in granuloma significantly correlated with the ratio of TNF-α/IL-10 in 
silicone-stimulated blood and submental skin of granuloma (blood, r=0.418,  p=0.019; 
submental skin of granuloma, r= -0.363, p=0.045). Based on data, IDO activity correlated 
with Treg function, thus the expression of IDO on inflammatory cell surface in granuloma 
can predict immune responses. 
2. Treg population in granuloma and submental skin did not correlate to the ratio of TNF-α/IL-
10 and IFN-γ/IL-10 in PHA-stimulated blood and silicone-stimulated silicone, as well as in 
granuloma and submental skin, but Treg population in granulomas inversely correlated with 
the ratio of TNF-α/IL-10 in blood plasma (r= - 0.460 p=0.009). This data prove that Treg 
function work through IL-10. 
The level of cytokines ratio in blood for granuloma prediction 
By assessing and comparing the inflammation that was occured with ability of the body to 
inhibit inflammation with anti inflammatory cytokines or tolerance mechanism, as played by 
IL-10 and IDO, the ratio of TNF-α/IL-10 or TNF-α/IDO would be more accurate to be used as 
predictive tool. Relationship between ratio of TNF-α/IL-10 and TNF-α/IDO with period of 
silicone injection can be seen in table 10. The ratio of TNF-α/IL-10 in PHA-stimulated blood 
and blood plasma and TNF-α/IDO in silicone-stimulated blood and blood plasma can be used 
as predictive tool. Inverse correlation means that the lower the ratio, the longer onset period of 
granuloma. 
According to the table 10, the ratio of TNF-α/IL-10 and TNF-α/IDO in blood plasma can be 
used as predictors of the onset period of granuloma (p=0.038; p=0.028). Table 1 showed the 
significant difference between the normal and granuloma patients. Ratio of TNF-α/IL-10 in 
blood plasma of normal patients differ significantly with granuloma patients (p=0.002). Ratio 
of TNF-α/IDO in blood plasma of normal patients differ significantly with granuloma patients 
(p=0.008). 
The level of cytokines in tissue  for granuloma prediction 
Tissue examination is required if there are any indecision in the existing examination, either 
physical or blood cytokine examination. 
Based on the results, in table 11, there was seen some cytokines correlated with clinical features 
and period of silicone injection. TNF-α expression on inflammatory cell surface in granuloma 
tissue significantly correlated with clinical features and period of silicone injection, but 
clinically most patients do not want to do the biopsy, i.e. at chin, so the submental skin of 
granuloma areas should be selected to represent the immune response that was occured. 
Based on table 11, Treg and IL-10 in submental skin of granuloma can be used as predictors 
of immune response that would happen. In accordance with the results, table 7 showed Treg 
had a significant correlation with  clinical severity of submental skin of granuloma, whereas 
IL-10 in submental skin of granuloma significantly correlated with IL-10 in the granuloma 
tissue. 
The numerical data need to be transformed to categorical data to measure prediction by mean 
of multivariate logistic regression. Treg population in submental skin of granuloma were 
splitted into two category with a cut-off limit 0.5 based on ROC analysis between Treg with 
the clinical features. 
Result of multivariate logistic regression analysis between clinical severity with IL-10 were 
obtained (IL-10 p=0.028 and Treg p=0.057). It was concluded that IL-10 in submental skin of 
granuloma can be used as the best predictor. Based on ROC analysis between IL-10 in 
submental skin of granuloma and clinical features, expression limit of IL-10 in submental skin 
of granuloma is 138. 
The higher degree of fibrosis showed immunologically improvement, but also became a 
problem for patients. IL-10 is an anti inflammatory cytokine and one of the cytokines produced 
by Treg, in addition to TGF-β.20,27,28 TGF-β played a role in fibrosis. If IL-10 level more than 
138 in submental skin of granuloma, granuloma did not need to be evacuated, actually. 
Evacuation procedure can be done on cosmetic indications, and must be followed-up through 
a standard blood test of normal patient, if IL-10 level less than 138, the patient should be 
recommended to treat with anti TNF-α or immunomodulatory, in order to avoid granuloma 
formation due to remaining-silicone in tissue. 
 Based on these data, cut off point for prediction of granuloma was establish. The median of 
ratios of granuloma patients can be used as  cut-off point for predicting the onset of granulomas. 
Cut off point ratio of TNF-α/IL-10=3.8 and TNF-α/IDO=0.1 as a lowest level. If the ratio below 
the cut off, so we need follow up every 6 month, if above the cut off, therpy anti TNF-α is 
needed. 
 
4. CONCLUSIONS 
1. Generally, patients with chin granuloma due to silicone injection were injected in the salon. 
They came for treatment approximately 12.5 years after injection, the  shape of chin changed 
in 4th years, the color of the skin changed in 5th years.  
2. Level of pro inflammatory cytokines tend to be higher in patients with granuloma due to 
silicone injection compared to the normal patients, while anti inflammatory cytokines levels 
of blood tend to be lower than normal patients. Histopathological features of granuloma 
caused by silicone are more inflammation, while nomal skin were more fibrosis. 
3. There is a significant correlation between proinflammatory cytokines TNF-α,  in blood with 
TNF-α expression on inflammatory cell surface in granuloma tissue. Level of TNF-α in 
blood can be used as predictor to assess the immune response due to silicone injection. 
4. IL-10 in submental skin of granulomas significantly correlated with cytokines in 
granulomas.  IL-10 played a role in submental skin of granuloma and can be used as the best 
predictor to assess the immune response in submental skin due to silicone injection. 
5. Clinical severity is significantly correlated with histopathological features of granuloma. 
Period of injection related with histopathologic features in granulomas and submental skin. 
Histopathological features in submental skin of granuloma associated with higher level of 
silicone.  
6. TNF-α played a role in immune response due to inflammation in granuloma, while IL-10. 
Treg cells and enzime IDO played a role in immune tolerance due to silicone injection. 
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